M. Wulfsohn

发表

G-Estimation of the Effect of Prophylaxis Therapy for Pneumocystis carinii Pneumonia on the Survival of AIDS Patients

J. Robins, D. Blevins, G. Ritter, 1992, Epidemiology.

The Relationship of CD4 Counts over Time to Survival in Patients with AIDS: Is CD4 a Good Surrogate Marker?

M. Wulfsohn, R. Strawderman, A. Tsiatis, 1992 .

A joint model for survival and longitudinal data measured with error.

M. Wulfsohn, A. Tsiatis, 1997, Biometrics.

Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS

M. Wulfsohn, A. Tsiatis, V. DeGruttola, 1995 .

Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

M. Wulfsohn, P. Marcellin, Z. Goodman, 2003, The New England journal of medicine.

Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients

M. Wulfsohn, E. Schiff, J. Villeneuve, 2003, Hepatology.

Considerations on Testing Secondary Endpoints in Group Sequential Design

M. Wulfsohn, G. Koch, Xiaoming Li, 2017 .

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

M. Wulfsohn, M. Hirsch, C. Parker, 1990, The New England journal of medicine.

Prevention of Relapse of Histoplasmosis with Itraconazole in Patients with the Acquired Immunodeficiency Syndrome

M. Wulfsohn, M. Saag, K. Squires, 1993, Annals of Internal Medicine.

Efficacy and Safety of Three Antiretroviral Regimens for Initial Treatment of HIV-1: A Randomized Clinical Trial in Diverse Multinational Settings

M. Wulfsohn, S. Hammer, R. Schooley, 2012, PLoS medicine.

Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B

M. Wulfsohn, C. Gibbs, Huiling Yang, 2003, Hepatology.

Patterns of Resistance Emerging in HIV-1 From Antiretroviral-Experienced Patients Undergoing Intensification Therapy With Tenofovir Disoproxil Fumarate

M. Wulfsohn, A. Cheng, N. Margot, 2004, Journal of acquired immune deficiency syndromes.

Phase II double-blind, placebo-controlled study of the safety and efficacy of cidofovir topical gel for the treatment of patients with human papillomavirus infection.

M. Wulfsohn, E. De Clercq, M. Van Ranst, 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

M. Wulfsohn, P. Marcellin, Z. Goodman, 2003, The New England journal of medicine.

Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

Histological improvement in HBeAg positive chronic hepatitis B patients treated with adefovir dipivoxil

M. Wulfsohn, P. Marcellin, Z. Goodman, 2002 .

241 Long-term (96 weeks) adefovir dipivoxil in HBEAG negative chronic hepatitis results in significant virological, biochemical and histological improvement

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, A. Neumann, 2003 .

Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients

M. Wulfsohn, C. Gibbs, W. Delaney, 2005, Journal of viral hepatitis.

GS-98-438 a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B: 48 week results

M. Wulfsohn, P. Marcellin, S. Lim, 2002 .

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

M. Wulfsohn, J. Kahn, S. Lagakos, 1999, JAMA.

1141 Complete genotypic and phenotypic analyses of HBV mutations identified in HBEAG-negative chronic hepatitis B patients receiving 96 weeks of adefovir dipivoxil (ADV)

M. Wulfsohn, C. Gibbs, P. Angus, 2003 .

Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B

M. Wulfsohn, P. Marcellin, S. Lim, 2003 .

Loss of lamivudine resistance mutations after patients switched to adefovir dipivoxil therapy

Michael I. Miller, M. Wulfsohn, C. Gibbs, 2002 .

Long-term HBV kinetics classification during treatment with adefovir dipivoxil

M. Wulfsohn, C. Gibbs, A. Neumann, 2002 .

Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy

M. Wulfsohn, C. Gibbs, Huiling Yang, 2003 .

Original Articles: Viral HepatitisAdefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre– and post–liver transplantation patients☆

M. Wulfsohn, E. Schiff, J. Villeneuve, 2003 .

10 Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment

M. Wulfsohn, J. Villeneuve, F. Zoulim, 2003 .

A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome

M. Wulfsohn, M. Hirsch, T. Merigan, 1990 .

A multicenter trial of oral zidovudine in children with advanced human immunodeficiency virus disease. The Protocol 043 Study Group.

M. Wulfsohn, R. Gelber, W. Borkowsky, 1991, The New England journal of medicine.

Phase II dose‐ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093)

Roger B. Davis, M. Wulfsohn, C. Crumpacker, 1994 .

Genotypic and phenotypic predictors of the magnitude of response to tenofovir disoproxil fumarate treatment in antiretroviral-experienced patients.

M. Wulfsohn, Shan-Shan Chen, A. Cheng, 2004, The Journal of infectious diseases.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Background: Resistance to antiretroviral agents remains a lead- ing cause of treatment failure for patients infected with HIV-1.

M. Wulfsohn, K. Squires, A. Pozniak, 2003 .

Efficacy and Safety of Adefovir Dipivoxil With Antiretroviral Therapy

Michael I. Miller, M. Wulfsohn, J. Kahn, 2017 .

Phase I/II study of the pharmacokinetics, safety and antiretroviral activity of tenofovir alafenamide, a new prodrug of the HIV reverse transcriptase inhibitor tenofovir, in HIV-infected adults.

William A. Lee, M. Wulfsohn, A. Zolopa, 2014, The Journal of antimicrobial chemotherapy.

Problems encountered in measuring erythrocyte pyrimidine 5'-nucleotidase activity.

M. Wulfsohn, J. Torrance, W. Mills, 1982, Analytical biochemistry.

Concordance of HIV-1 RNA Values by Amplicor and TaqMan 2.0 in Patients With Confirmed Suppression in Clinical Trials.

M. Wulfsohn, K. White, Lijie Zhong, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Attention, arousal, and memory in posttraumatic stress disorder

M. Wulfsohn, D. Herman, B. Litz, 1996, Journal of traumatic stress.